| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Chest Department, Hôpital Arnaud de Villeneuve, 34294, Montpellier, France
2 From The Cancer Institute, Montpellier, France
3 From the Institut Gustave Roussy, Villejuif, France
Thirty-three patients with T3, N2, M0 or T4, N2, M0, nonsmall-cell lung cancer (NSCLC) took part in a phase 2 study in an attempt to evaluate the feasability of neoadjuvant chemotherapy followed by surgery and thoracic radiotherapy. Chemotherapy consisted of daily administration of the following treatment: etoposide, 100 mg/m2; cisplatin, 25 mg/m2; ifosfamide, 1.5 g/m2; and mesna, 1.8 g/m2 for 4 days. Three cycles were planned starting every 21 days. Responding patients underwent a thoracotomy in order to attempt a resection and then received a 45 Gy of thoracic radiotherapy. The results of response and resection rates have been published and the present final report deals with the longterm results. Chemotherapy induced a 55 percent partial response rate and a 15 percent complete response rate allowing a complete resection in 55 percent of the patients. Complete remission was histologically confirmed for the five complete responders. Although the median survival was short (10 months), six patients were long-term survivors (3-year survival rate: 19 percent). Survival was significantly influenced by the type of resection: patients for whom a complete resection was possible survived the longest with a median survival three times that of the other patients. Modalities of relapses differed according to the results of surgery: 8 of the 15 patients who did not undergo a complete surgical resection experienced a local relapse during the first 18 months of follow-up whereas in the complete resection group, central nervous system metastasis was the main site of relapse. We conclude that the neoadjuvants ifosfamide, cisplatin, and etoposide in patients with locally advanced NSCLC are feasible to use and allow a 19 percent 3-year survival rate. These results are the rationale of an ongoing randomized study comparing neoadjuvant chemotherapy followed by surgery and surgery alone. This study is designed to test whether neoadjuvant chemotherapy improves survival of patients with locally advanced NSCLC.
Key Words: feasibility • neoadjuvant chemotherapy • nonsmall-cell lung cancer (NSCLC) • surgery • TNM classification
Submitted on December 3, 1992
Accepted on February 25, 1994
This article has been cited by other articles:
|
|
 |
|
  I. S. Choi, D.-Y. Oh, J. H. Kwon, S.-I. Kim, S. R. Park, J.-Y. Bak, J. H. Kim, D.-W. Kim, Y. T. Kim, T.-Y. Kim, et al. Paclitaxel/Platinum-based Perioperative Chemotherapy and Surgery in Stage IIIA Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., January 1, 2005; 35(1): 6 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. De Leyn, J. Vansteenkiste, G. Deneffe, D. Van Raemdonck, W. Coosemans, and T. Lerut Result of induction chemotherapy followed by surgery in patients with stage IIIA N2 NSCLC: importance of pre-treatment mediastinoscopy Eur. J. Cardiothorac. Surg., May 1, 1999; 15(5): 608 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Vansteenkiste, P. De Leyn, G. Deneffe, J. Menten, T. Lerut, and M. Demedts Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: a review Eur. J. Cardiothorac. Surg., January 1, 1998; 13(1): 1 - 12. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
